Drug Information

Drug General Information
Drug ID
D07YHY
Former ID
DIB013013
Drug Name
CR-2093
Drug Type
Small molecular drug
Indication Intestine cancer [ICD10:C17-C20, C26] Discontinued in Phase 1 [544899]
Company
Rotta Research Lab SpA
Formula
C18H25ClN2O4
Canonical SMILES
C(=O)(N[C@@H](C(=O)NCCC(C)(C)C)CCC(=O)O)c1cc(Cl)ccc1
CAS Number
CAS 136374-73-7
PubChem Compound ID
131954
Target and Pathway
Target(s) Gastrin/cholecystokinin type B receptor Target Info Modulator [533774]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gastric acid secretion
PANTHER Pathway CCKR signaling map ST
PathWhiz Pathway Gastric Acid Production
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
Gastrin-CREB signalling pathway via PKC and MAPK
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Secretion of Hydrochloric Acid in Parietal Cells
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 544899Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001442)
Ref 533774Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.